Paper Details

  1. Home
  2. Paper Details

Evidence-based pharmacotherapy of Alzheimer's disease.

Author: BirksJacqueline, EvansJohn Grimley, WilcockGordon

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Dementia is a serious condition affecting thinking and memory, with Alzheimer’s disease being the most common cause. While descriptions of Alzheimer’s disease have improved, there is no specific test to diagnose it. Current treatments aim to manage symptoms and include medications that increase acetylcholine levels in the brain. These medications have modest benefits for thinking and daily activities but can cause significant side effects. Another medication, memantine, has shown similar benefits to cholinesterase inhibitors and is approved for treating moderate to severe Alzheimer’s disease. Other treatments, such as vitamins, herbs, and anti-inflammatory drugs, have not been proven effective.
Paper Details　
Original Abstract of the Article :
Dementia is an acquired global impairment of cognitive capacities. Approximately 5% of people aged over 65 yr are affected by dementia, and some 70% of cases are thought to be due primarily to Alzheimer's disease. Descriptions of the clinical manifestations of Alzheimer's disease have been increasin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15228642

データ提供：米国国立医学図書館（NLM）

Pharmacotherapy for Alzheimer's Disease

Alzheimer's disease, a devastating neurodegenerative disorder, can be like a slow-moving sandstorm, gradually eroding cognitive function and memory. This study examines the current state of pharmacotherapy for Alzheimer's disease, focusing on cholinesterase inhibitors and memantine. The authors highlight the limitations of current treatments and emphasize the need for ongoing research to develop more effective therapies.

Cholinesterase Inhibitors and Memantine: A Temporary Oasis

The study suggests that cholinesterase inhibitors and memantine can provide some temporary relief from the symptoms of Alzheimer's disease, but they do not offer a cure. It's like finding a small oasis in the midst of a vast and unforgiving desert, offering a brief respite from the relentless heat and thirst, but not a permanent solution to the challenges of the journey.

The Importance of Continued Research

The researchers emphasize the importance of continued research to develop new and more effective treatments for Alzheimer's disease. It's like searching for a larger and more sustainable oasis in the desert, a place that can offer lasting relief and improve the quality of life for those affected by this devastating condition.

Dr.Camel's Conclusion

The desert of Alzheimer's disease is a daunting landscape, but researchers are tirelessly working to find new pathways to relief. While current medications offer some temporary benefits, the quest for a cure continues, driven by a deep commitment to improving the lives of those affected by this devastating condition.
Date :
  1. Date Completed 2004-10-27
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

15228642

DOI: Digital Object Identifier

S1461145704004444

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.